Phase 2 N=68 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Acute Myeloid Leukemia · Myelodysplastic Syndromes · Agnogenic Myeloid Metaplasia
Primary: Participant Response Rate — 1; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=234 Myeloproliferative Neoplasms: an In-depth Case-control Study
Polycythemia Vera · Essential Thrombocythemia · Primary Myelofibrosis
Primary: Influence of Pre- and Post- Incentives on Participation Rates. — 4; 6; 15; 69 Participants
Phase 2 N=83 Pegasys® in Patients With Myeloproliferative Diseases
Myeloproliferative Disorders
Primary: Number of Patients With Complete Response (CR) or Partial Response (PR) — 3; 3; 14; 23 Participants
Phase 3 N=51 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Phase 1 N=35 Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Primary Myelofibrosis (PMF) · Post-Polycythaemia Vera · Essential Thrombocythaemia Myelofibrosis
Primary: Pharmacokinetic Parameters Following Single Dosing: AUC0-12 — 69.2; 295; 278; 1860 ug*h/L
Phase 2 N=29 Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Myeloproliferative Diseases
Primary: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response — 2; 12; 2; 1 Participants
Phase 2 N=66 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Phase 2 N=154 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
Phase 2 N=22 A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…
Phase 2 N=30 A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Phase 3 N=670 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants
Phase 2 N=77 Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants
N/A N=125 Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Phase 2 N=10 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Chronic Phase Myelofibrosis · Primary Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Primary: European Leukemia Net -International Working Group (ELN-IWG) Criteria — 0 Participants
Phase 4 N=48 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Phase 2 N=10 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria — 10 percentage of participants
Phase 2 N=22 CEP-701 for PH-negative Myelofibrosis
Leukemia · Myelofibrosis
Primary: Number of Participants With Objective Response — 0; 0; 6 Participants
Phase 3 N=21 Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Phase 2 N=74 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Phase 2 N=120 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Phase 1 N=69 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 2 N=35 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Phase 3 N=168 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
High Risk Polycythemia Vera · High Risk Essential Thrombocythemia
Primary: Number of Participants With Complete Remission (CR) — 17; 19; 12; 13 Participants
Phase 3 N=267 Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
Primary Myelofibrosis · MPN-associated Myelofibrosis
Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000
Phase 2 N=41 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Myelofibrosis
Primary: Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 — 78.0 Percentage of participants
Phase 1 N=46 Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Phase 2 N=41 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) Myelofibrosis · Postessential Thrombocythemia (Post-ET) Myelofibrosis
Primary: Transfusion Independence Response by Week 24 — 34.1 percentage of subjects
Phase 4 N=146 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Thrombocythemia, Hemorrhagic
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time — 66.4; 66.9; 0.5; -1.1 percentage of ejection fraction
Phase 3 N=611 Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Phase 2 N=12 Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants